Collaborative and Other Relationships - Samsung Bioepis (Details) $ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|---|
|
Dec. 31, 2019
product
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
|
|
| Collaborative arrangements and non-collaborative arrangement transactions | ||||||
| Collaboration profit sharing/(loss reimbursement) | $ 77.8 | $ 87.2 | $ 220.8 | $ 220.3 | ||
| Samsung Bioepis | ||||||
| Collaborative arrangements and non-collaborative arrangement transactions | ||||||
| Collaboration profit sharing/(loss reimbursement) | 49.0 | $ 66.5 | $ 151.1 | $ 171.7 | ||
| Samsung Bioepis | ||||||
| Collaborative arrangements and non-collaborative arrangement transactions | ||||||
| Contingent Commercialized Rights, Number Of Products | product | 2 | |||||
| Expected profit share percentage | 45.00% | 50.00% | ||||
| Collaboration agreement term | 5 years | |||||
| Samsung Bioepis | Related Party | ||||||
| Collaborative arrangements and non-collaborative arrangement transactions | ||||||
| Accounts receivable | 3.8 | $ 3.8 | $ 4.4 | |||
| Accounts payable | $ 145.9 | $ 145.9 | $ 42.7 | |||